Duchenne Muscular Dystrophy (DMD) Therapeutics Global Market Report 2024

The global duchenne muscular dystrophy (dmd) therapeutics market has grown exponentially in recent years. It will grow from $8.64 billion in 2023 to $11.95 billion in 2024 at a compound annual growth rate (CAGR) of 38.4%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, awareness about duchenne muscular dystrophy treatment, rising healthcare spending, government initiatives.

The global duchenne muscular dystrophy (dmd) therapeutics market is expected to see exponential growth in the next few years. It will grow to $36.72 billion in 2028 at a compound annual growth rate (CAGR) of 32.4%. The growth in the forecast period can be attributed to growing investments in for duchenne muscular dystrophy treatments, adoption of combination therapies, emergence of biomarker,growing number of screening programs for duchenne muscular dystrophy. Major trends in the forecast period include innovative treatments for duchenne muscular dystrophy, development of targeted therapies, introduction of novel medications and therapies, innovative disease-modifying therapies, active drug developments.

The growth of the Duchenne muscular dystrophy (DMD) therapeutics market is anticipated to be propelled by the increasing number of clinical trials. Clinical trials represent essential research studies involving human participants aimed at assessing the safety, efficacy, and potential advantages of new medical treatments, interventions, or medications. The upsurge in clinical trials dedicated to exploring Duchenne muscular dystrophy treatments underscores the ongoing commitment to research, innovation, and a diverse range of therapeutic possibilities. This trend is poised to result in improved patient outcomes, heightened investments, and the accelerated development and accessibility of effective DMD therapies. For example, in August 2023, as reported by Clinicaltrials.gov, a branch of the National Institutes of Health (NIH), the number of registered clinical trials has increased to 464,218, marking a significant rise from 399,496 in 2021. These trials are conducted across all 50 states of the United States and in 221 countries. Additionally, 31% of these studies, totaling 142,700, are registered within the U.S., while the remaining 53% of studies (248,310) are documented in international locations. Consequently, the escalating count of clinical trials is expected to be a driving force behind the expansion of the Duchenne muscular dystrophy (DMD) therapeutics market.

The increasing occurrence of genetic disorders is poised to fuel the growth of the Duchenne muscular dystrophy (DMD) market in the years to come. Genetic disorders encompass a range of medical conditions stemming from abnormalities or mutations in an individual's DNA or genetic material. As the prevalence of genetic disorders continues to rise, a larger segment of the population becomes susceptible to DMD due to genetic mutations or familial genetic predispositions. Consequently, this upward trend is expected to drive greater demand for DMD-related diagnostics, treatments, and therapeutic solutions. For instance, in 2021, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that birth defects affect approximately 3% of all babies born in the United States each year, totaling one in every 33 babies. Furthermore, these defects are the primary cause of infant mortality, accounting for 20% of all infant deaths. Thus, the increasing prevalence of genetic disorders is a key factor propelling the expansion of the Duchenne muscular dystrophy (DMD) market.

The high cost of treatment can potentially limit access to care and may act as a restraining factor for the growth of the Duchenne muscular dystrophy (DMD) therapeutics market during the projected period. The elevated cost of therapeutics for Duchenne muscular dystrophy (DMD) presents a substantial obstacle for patients. It can lead to reduced demand for treatment, delays in both diagnosis and therapy, financial strain on patients, restricted access to healthcare, constrained market expansion, increased healthcare expenditures, and an overall reduction in the quality of life. For example, as of February 2023, the Institute for Clinical and Economic Review (ICER), a U.S.-based non-profit organization, reported that the average cost of a gene therapy dose falls in the range of $1 million to $2 million. Thus, the high cost of treatment poses a hindrance to the growth of the Duchenne muscular dystrophy (DMD) therapeutics market.

The leading companies in the field of Duchenne muscular dystrophy (DMD) therapeutics are embracing innovative technologies to enhance the effectiveness and accessibility of treatments for DMD patients while maintaining their competitive edge in the market. A case in point is Bit Bio Ltd., a UK-based synthetic biology company, which, in July 2023, introduced disease model products aimed at advancing Duchenne muscular dystrophy (DMD) treatments. These disease models, specifically the ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, consist of human skeletal myocytes engineered to carry deletions in the gene responsible for dystrophin protein production. Derived from induced pluripotent stem cells (iPSCs), Bit Bio's models offer a reliable and scalable source of human cells for research, addressing challenges associated with variability and the sourcing of primary cells. These models provide valuable insights into disease mechanisms and potential therapies, supporting the development of treatments for DMD. This technological advancement has the potential to expedite the work of researchers striving to find effective solutions for Duchenne muscular dystrophy.

In December 2022, Solid Biosciences Inc., a biotechnology firm headquartered in the United States, successfully completed the acquisition of AavantiBio, Inc. The financial details of the transaction remain undisclosed. This acquisition represents a significant move by Solid Biosciences to extend its collection of gene therapy programs, focusing on neuromuscular and cardiac diseases. The incorporation of AavantiBio, Inc. has not only broadened the company's capabilities but also brought in valuable expertise and financial resources for advancing research and development efforts and reaching potential milestones. AavantiBio, Inc., a gene therapy company based in the United States, specializes in the development of groundbreaking treatments for Duchenne muscular dystrophy and various other neuromuscular and cardiac diseases.

Major players in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings plc, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.

North America was the largest region in the DMD therapeutics market in 2023. The regions covered in duchenne muscular dystrophy (DMD) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the duchenne muscular dystrophy (DMD) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.

The principal categories of DMD therapeutics consist of small molecules and biologics. Small molecules are compounds with low molecular weight that can specifically interact with certain proteins or targets within the body. These can be tailored to address various facets of DMD, such as mitigating inflammation, fostering muscle regeneration, or targeting specific genetic mutations. The distribution of these therapeutics occurs through both offline and online channels, catering to applications in hospitals, clinics, and home care settings.

This report provides duchenne muscular dystrophy (DMD) therapeutics market statistics, including duchenne muscular dystrophy (DMD) therapeutics industry global market size, regional shares, competitors with a duchenne muscular dystrophy (DMD) therapeutics market share, detailed duchenne muscular dystrophy (DMD) therapeutics market segments, market trends and opportunities and any further data you may need to thrive in the duchenne muscular dystrophy (DMD) therapeutics industry. This duchenne muscular dystrophy (DMD) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy (DMD) therapeutics market includes revenues earned by entities by providing services including gene therapies, genetic testing and counseling, telehealth and remote monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The duchenne muscular dystrophy (DMD) therapeutics market also include sales of casimersen, eteplirsen and golodirsen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.